Skip to content
RDL Network logo
1721MO Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma — Rhonda Jones (2024) | RDL Network